Last week's biggest headline deals occupied the fields of cancer and dementia, while a host of smaller deals included several targeting infectious diseases affecting developing countries, and vaccine and manufacturing technologies were much in evidence.

Nuron Biotech, a two-year old privately held US biologics and vaccines company, has brought in another licensing deal. It has licensed from Vitruvian BioMedical a gene-based amyloid 42 (Abeta42) vaccine that is in preclinical development for Alzheimer's disease. Nuron obtained an exclusive, worldwide licence for the vaccine and is responsible for the development and commercialisation.

Nuron Biotech, a two-year old privately held US biologics and vaccines company, has brought in its first licensing deal. It has signed an agreement with Mitsubishi Tanabe Pharma of Osaka, Japan, to commercialise its HibTiter vaccine (Haemophilus b conjugate vaccine [diphtheria CRM197 protein conjugate]) in Japan, both as a single entity and for combination product use.

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.